Weight loss medications like Wegovy, known for increasing satiety and aiding weight loss, are now linked to altered food preferences, with users reporting a decreased desire for previously enjoyed foods. This observation is supported by emerging research indicating that GLP-1 analogs, such as those found in Wegovy, can change taste preferences.

Research suggests that fatty and starchy foods, soda, and sweets are particularly affected, becoming less appealing to individuals on these medications. Studies have demonstrated changes in taste perception and brain activity related to sweets in women using semaglutide, the active ingredient in Wegovy. Furthermore, research involving Japanese patients with type 2 diabetes revealed a significant reduction in cravings for chocolate, sweet, and starchy foods after three months of medication use. Novo Nordisk’s own trials have also shown a decrease in cravings for salty, spicy, dairy-based, and starchy foods compared to placebo groups.

While the exact mechanism behind these changes remains unclear, one explanation is that the increased feeling of fullness diminishes the desire for sweets. An alternative, and potentially more significant, explanation points to the medication’s impact on the brain’s reward center.

Studies indicate that weight loss medications can inhibit reward responses associated with substances like nicotine and alcohol. This effect has spurred research into the potential use of these medications for addiction treatment. For example, studies have shown that semaglutide can significantly reduce alcohol intake in people with alcohol dependence. Additionally, GLP-1 analogs have been associated with a lower overdose rate among people with opioid dependence.

Researchers suggest that the same mechanism may explain why some individuals no longer enjoy foods that previously triggered dopamine release in the reward center. Another possible factor is the impact of the medication on FGF-21, a hormone-like substance that plays a role in the desire for sweets. While research indicates that this substance is affected by weight loss medication, its precise significance is still under investigation.

It is important to note that, Wegovy is currently approved for the treatment of obesity and related conditions, and studies are ongoing to investigate the use in addiction treatment.